Lower blood pressure targets delivers significantly larger heart health benefits than previously believed, says a new study. They found that keeping blood pressure below 120 mm Hg reduces the risk of heart attack and stroke. This intensive target also lowers the likelihood of heart failure more effectively than higher clinical targets.
Scientists used large datasets and simulation models to evaluate the impact of different systolic blood pressure goals.
Modeling the Future of Heart Health
Researchers analyzed data from the Systolic Blood Pressure Intervention Trial (SPRINT) and the National Health and Nutrition Examination Survey. They used this information to model lifetime outcomes for heart attacks, strokes, and heart failure cases. The study compared three specific systolic targets: less than 120, 130, and 140 mm Hg. By simulating these outcomes, the team provided a clearer picture of long-term cardiovascular health.
Balancing Benefits Against Treatment Risks
The team recognized that aggressive blood pressure medications often cause significant side effects in many patients. Consequently, the model included the potential for serious complications linked directly to intensive medication use. Researchers weighed the prevention of cardiovascular events against the possible harms of treatment. This balanced approach ensures that the findings reflect the complexities of modern medical care.
Accounting for Real-World Errors
Blood pressure readings in routine clinical settings often contain common inaccuracies and measurement errors. The researchers incorporated these real-world errors into their analysis to mirror actual doctor-patient interactions. Even after factoring in these errors, the model favored the lower target of 120 mm Hg. This intensive goal prevented more heart attacks and strokes than aiming for a target of 130 mm Hg.
The Downside of Intensive Control
While the benefits are clear, the more aggressive target is not without its specific downsides. Patients faced a higher likelihood of experiencing falls, kidney injury, hypotension, and bradycardia. Additionally, pursuing a lower target increases overall healthcare costs due to more frequent doctor visits. Patients also required a greater volume of antihypertensive medications to maintain these lower levels.
A Cost-Effective Solution for Longevity
Despite the added expenses, the researchers found that the lower target remains highly cost-effective. The estimated cost was approximately $42,000 per quality-adjusted life-year gained during the study. This figure is a commonly used measure to determine the overall value of healthcare interventions. Therefore, the intensive target provides good value under typical clinical and economic conditions.
Critical Analysis
This simulation study provides a compelling case for lowering systolic blood pressure targets to under 120 mm Hg. By utilizing data from major trials like SPRINT, the researchers have grounded their models in high-quality evidence. The inclusion of “real-world measurement errors” is particularly innovative, as it addresses a common criticism of clinical trials.
However, the findings rely heavily on simulation models rather than new, long-term prospective trials. While the cost-effectiveness appears favorable, the increased risk of falls and kidney injury in older populations cannot be overlooked. As lead author Karen Smith emphasizes, these population-level findings must be balanced against individual patient preferences and tolerances. Clinicians must remain vigilant, ensuring that the drive for lower numbers does not compromise a patient’s overall quality of life.
Q&A: Navigating New Blood Pressure Goals
Q: Why is the 120 mm Hg target being recommended now?
A: New simulations show it prevents significantly more heart attacks and strokes compared to the standard 130 or 140 targets.
Q: Are there risks to lowering blood pressure too much?
A: Yes, intensive treatment can lead to side effects like dizziness, falls, and potential kidney injury.
FAQ
Who should pursue the 120 mm Hg target?
This study focuses on patients at high cardiovascular risk, but individual plans should be discussed with a doctor.
Is intensive treatment expensive?
While it increases medication and visit costs, it is considered cost-effective relative to the health years gained.
What if my blood pressure readings are inconsistent?
The study found that the benefits of the lower target remain valid even when clinical measurements are not perfect.
